Latest Licensing News

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Aerometrex delivered a landmark FY26 with operating revenue up 12.3% to $26.84 million and EBITDA more than doubling to $7.68 million, driven by a 27.2% jump in MetroMap subscription revenue and a 37.8% rise in Annual Contract Value.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.

Sports Entertainment Group (ASX:SEG) posted a 39% revenue jump and 73% underlying EBITDA growth in FY26, offset by a 93% net profit decline due to tax and one-off impacts. The company is poised for growth with key acquisitions including MediaWorks NZ and the GIANTS Netball license.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

TALi Digital Limited (ASX: TD1) posted a 416% jump in revenue for FY26 but also recorded a $2.2 million loss driven by a $1.3 million impairment of its YCDI! intangible assets. The company is pursuing growth through AI-focused acquisitions and a $3.3 million capital raise.

Ainsworth Game Technology’s first half 2026 results reveal a sharp revenue drop driven by North American and Latin American market pressures, offset partially by Asia Pacific growth and a key patent licensing deal.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Calix Limited posted a 16% revenue increase to $39.2 million in FY26 driven by strong growth in its Magnesia business, while reporting a substantial net loss of $51 million largely due to a one-off impairment. The company advanced key industrial decarbonisation projects and strengthened strategic partnerships, focusing on capital-light commercialisation.

WiseTech Global posted a record $1.4 billion in revenue for FY26, driven by the e2open acquisition and AI-led efficiencies, while underlying net profit rose 29%. The company outlines a confident FY27 growth outlook amid ongoing integration and innovation.

Nine Entertainment Co. Holdings Limited posted a $511 million statutory net profit for FY26, driven by significant portfolio restructuring and growth in digital and outdoor advertising, while advancing AI licensing partnerships.